Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
uniQure ( (QURE) ) has provided an announcement.
On July 29, 2025, uniQure N.V. announced a sales agreement with Leerink Partners LLC for an at-the-market offering program, allowing the company to sell its ordinary shares worth up to $200 million. This strategic move provides uniQure with flexibility in raising capital, potentially enhancing its financial position and supporting its ongoing operations in the competitive gene therapy market.
The most recent analyst rating on (QURE) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.
Spark’s Take on QURE Stock
According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.
uniQure’s overall stock score reflects a challenging financial position with persistent losses and negative equity, which weigh heavily on the score. However, positive developments in its gene therapy pipeline, regulatory progress, and strong cash reserves provide potential for future growth, balancing some of the financial risks.
To see Spark’s full report on QURE stock, click here.
More about uniQure
uniQure N.V. operates in the biotechnology industry, focusing on the development and commercialization of gene therapies. The company is known for its innovative approach to treating genetic diseases and has a significant presence in the market for gene therapy solutions.
Average Trading Volume: 1,476,386
Technical Sentiment Signal: Buy
Current Market Cap: $820.1M
Learn more about QURE stock on TipRanks’ Stock Analysis page.